Kevin Gray to Treatment Outcome
This is a "connection" page, showing publications Kevin Gray has written about Treatment Outcome.
Connection Strength
1.260
-
ADHD symptoms and smoking outcomes in a randomized controlled trial of varenicline for adolescent and young adult tobacco cessation. Drug Alcohol Depend. 2023 03 01; 244:109798.
Score: 0.093
-
Latency to cannabis dependence mediates the relationship between age at cannabis use initiation and cannabis use outcomes during treatment in men but not women. Drug Alcohol Depend. 2021 01 01; 218:108383.
Score: 0.080
-
High-dose and low-dose varenicline for smoking cessation in adolescents: a randomised, placebo-controlled trial. Lancet Child Adolesc Health. 2020 11; 4(11):837-845.
Score: 0.079
-
Efficacy and Safety of Varenicline for Adolescent Smoking Cessation: A Randomized Clinical Trial. JAMA Pediatr. 2019 12 01; 173(12):1146-1153.
Score: 0.075
-
Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder. Psychopharmacology (Berl). 2020 Feb; 237(2):479-490.
Score: 0.075
-
Adolescent Substance Use Disorder Treatment: an Update on Evidence-Based Strategies. Curr Psychiatry Rep. 2019 09 14; 21(10):96.
Score: 0.074
-
The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug Alcohol Depend. 2018 04 01; 185:17-22.
Score: 0.066
-
A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017 08 01; 177:249-257.
Score: 0.063
-
Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation. Addict Behav. 2016 12; 63:172-7.
Score: 0.059
-
Increasing progesterone levels are associated with smoking abstinence among free-cycling women smokers who receive brief pharmacotherapy. Nicotine Tob Res. 2015 Apr; 17(4):398-406.
Score: 0.054
-
An exploratory short-term double-blind randomized trial of varenicline versus nicotine patch for smoking cessation in women. Addiction. 2015 Jun; 110(6):1027-34.
Score: 0.054
-
Cognitive performance in a placebo-controlled pharmacotherapy trial for youth with marijuana dependence. Addict Behav. 2015 Jun; 45:119-23.
Score: 0.053
-
An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers. Am J Drug Alcohol Abuse. 2015 Jan; 41(1):52-6.
Score: 0.052
-
Cigarette smoking during an N-acetylcysteine-assisted cannabis cessation trial in adolescents. Am J Drug Alcohol Abuse. 2014 Jul; 40(4):285-91.
Score: 0.051
-
Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs. 2014 Feb; 28(2):95-106.
Score: 0.050
-
Smoking topography and abstinence in adult female smokers. Addict Behav. 2013 Dec; 38(12):2833-6.
Score: 0.048
-
A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012 Aug; 169(8):805-12.
Score: 0.045
-
Varenicline versus bupropion XL for smoking cessation in older adolescents: a randomized, double-blind pilot trial. Nicotine Tob Res. 2012 Feb; 14(2):234-9.
Score: 0.042
-
Bupropion SR and contingency management for adolescent smoking cessation. J Subst Abuse Treat. 2011 Jan; 40(1):77-86.
Score: 0.040
-
Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder. Psychol Addict Behav. 2022 Aug; 36(5):505-514.
Score: 0.021
-
Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials. Drug Alcohol Depend. 2018 06 01; 187:270-277.
Score: 0.017
-
A multi-site proof-of-concept investigation of computerized approach-avoidance training in adolescent cannabis users. Drug Alcohol Depend. 2018 06 01; 187:195-204.
Score: 0.017
-
Vilazodone for cannabis dependence: A randomized, controlled pilot trial. Am J Addict. 2016 Jan; 25(1):69-75.
Score: 0.014
-
Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. Drug Alcohol Depend. 2015 Nov 01; 156:29-37.
Score: 0.014
-
Cognitive training as a resolution for early executive function difficulties in children with intellectual disabilities. Res Dev Disabil. 2015 Mar; 38:145-60.
Score: 0.013
-
Changes in cardiovascular risk factors with participation in a 12-week weight loss trial using a commercial format. Eat Behav. 2014 Jan; 15(1):68-71.
Score: 0.012